Semaglutide TFA, a long-acting GLP-1 analogue, is a Glukagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment.Appearance:SolidIC50& Target:GLP-1 receptor .In Vitro:Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib 8 , Arg 34 ) and is derivatized at lysine 26. The GLP-1R affinity of Semaglutide is 0.38±0.06 nM. Semaglutide is a GLP-1 analogue with 94% sequence omology to human GLP-1.In Vivo:The plasma half-life of Semaglutide is 46h in mini-pigs following i.v. administration and semaglutide has an MRT of 63.6h after s.c. dosing to mini-pigs . Semaglutide improves 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced motor impairmeBiological Activity:Semaglutide TFA, a long-acting GLP-1 analogue, is a Glukagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide TFA has the potential for type 2 diabetes treatment. Specification: 0.99 Molecular Formula: C189H292F3N45O61 Molecular Weight: 4227.66
- UPC:
- 41116010
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.09 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- S659061-5mg
- Product Size:
- 5mg
